Identification of Conserved and HLA Promiscuous DENV3 T-Cell Epitopes

PLoS Neglected Tropical Diseases

Volumn 7, Issue 10, 2013, Pages

  Nascimento, Eduardo J M ^a   Mailliard, Robbie B ^a   Khan, Asif M ^b,c   Sidney, John ^d   Sette, Alessandro ^d   Guzman, Nicole ^e   Paulaitis, Michael ^e   de Melo, Andréa Barbosa ^f   Cordeiro, Marli T ^f   Gil, Laura V G ^f   Lemonnier, Françoir ^g   Rinaldo, Charles ^a   August, J Thomas ^b   Marques Jr , Ernesto T A ^a,f  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c PERDANA UNIVERSITY   (Malaysia)

^d LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^e The Ohio State University   (United States)

^f INSTITUTO OSWALDO CRUZ   (Brazil)

^g INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B7 ANTIGEN; HLA DR2 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5; PROTEOME; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 3; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; HLA TYPING; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; PEPTIDE LIBRARY; SEROTYPE; T LYMPHOCYTE;

ADOLESCENT; ADULT; ANIMALS; ANTIGENS, VIRAL; CHILD; DENGUE VIRUS; ENZYME-LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MICE; MICE, TRANSGENIC; PHOSPHOPROTEINS; PROTEIN BINDING;

EID: 84887295672     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002497     Document Type: Article

References (76)

1. Ashour J, Laurent-Rolle M, Shi PY, Garcia-Sastre A, (2009) NS5 of dengue virus mediates STAT2 binding and degradation. J Virol 83: 5408-5418.
2. Mazzon M, Jones M, Davidson A, Chain B, Jacobs M, (2009) Dengue virus NS5 inhibits interferon-alpha signaling by blocking signal transducer and activator of transcription 2 phosphorylation. J Infect Dis 200: 1261-1270.
3. Rodriguez-Madoz JR, Bernal-Rubio D, Kaminski D, Boyd K, Fernandez-Sesma A, (2010) Dengue virus inhibits the production of type I interferon in primary human dendritic cells. J Virol 84: 4845-4850.
4. Khan AM, Heiny AT, Lee KX, Srinivasan KN, Tan TW, et al. (2006) Large-scale analysis of antigenic diversity of T-cell epitopes in dengue virus. BMC Bioinformatics 7 Suppl 5: S4.
5. Whitehead SS, Blaney JE, Durbin AP, Murphy BR, (2007) Prospects for a dengue virus vaccine. Nat Rev Microbiol 5: 518-528.
6. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, et al. (2004) Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 189: 990-1000.
7. Pang T, Cardosa MJ, Guzman MG, (2007) Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Immunol Cell Biol 85: 43-45.
8. Chaturvedi UC, Shrivastava R, Nagar R, (2005) Dengue vaccines: problems and prospects. Indian J Med Res 121: 639-652.
9. Simmons CP, Dong T, Chau NV, Dung NT, Chau TN, et al. (2005) Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J Virol 79: 5665-5675.
10. Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, et al. (2009) A protective role for dengue virus-specific CD8+ T cells. J Immunol 182: 4865-4873.
11. Yauch LE, Prestwood TR, May MM, Morar MM, Zellweger RM, et al. (2010) CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol 185: 5405-5416.
12. Rothman AL, (2011) Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 11: 532-543.
13. Green S, Kurane I, Pincus S, Paoletti E, Ennis FA, (1997) Recognition of dengue virus NS1-NS2a proteins by human CD4+ cytotoxic T lymphocyte clones. Virology 234: 383-386.
14. Mathew A, Kurane I, Green S, Stephens HA, Vaughn DW, et al. (1998) Predominance of HLA-restricted cytotoxic T-lymphocyte responses to serotype-cross-reactive epitopes on nonstructural proteins following natural secondary dengue virus infection. J Virol 72: 3999-4004.
15. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, et al. (2003) Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 9: 921-927.
16. Mongkolsapaya J, Duangchinda T, Dejnirattisai W, Vasanawathana S, Avirutnan P, et al. (2006) T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J Immunol 176: 3821-3829.
17. Weiskopf D, Yauch LE, Angelo MA, John DV, Greenbaum JA, et al. (2011) Insights into HLA-Restricted T Cell Responses in a Novel Mouse Model of Dengue Virus Infection Point toward New Implications for Vaccine Design. J Immunol 187: 4268-4279.
18. Zivna I, Green S, Vaughn DW, Kalayanarooj S, Stephens HA, et al. (2002) T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity. J Immunol 168: 5959-5965.
19. Li S, Peng L, Zhao W, Zhong H, Zhang F, et al. (2011) Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses. Vaccine 29: 3695-3702.
20. Bashyam HS, Green S, Rothman AL, (2006) Dengue virus-reactive CD8+ T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes. J Immunol 176: 2817-2824.
21. Chotiyarnwong P, Stewart-Jones GB, Tarry MJ, Dejnirattisai W, Siebold C, et al. (2007) Humidity control as a strategy for lattice optimization applied to crystals of HLA-A*1101 complexed with variant peptides from dengue virus. Acta Crystallogr Sect F Struct Biol Cryst Commun 63: 386-392.
22. Imrie A, Meeks J, Gurary A, Sukhbataar M, Kitsutani P, et al. (2007) Differential functional avidity of dengue virus-specific T-cell clones for variant peptides representing heterologous and previously encountered serotypes. J Virol 81: 10081-10091.
23. Kurane I, Dai LC, Livingston PG, Reed E, Ennis FA, (1993) Definition of an HLA-DPw2-restricted epitope on NS3, recognized by a dengue virus serotype-cross-reactive human CD4+ CD8- cytotoxic T-cell clone. J Virol 67: 6285-6288.
24. Kurane I, Zeng L, Brinton MA, Ennis FA, (1998) Definition of an epitope on NS3 recognized by human CD4+ cytotoxic T lymphocyte clones cross-reactive for dengue virus types 2, 3, and 4. Virology 240: 169-174.
25. Mangada MM, Rothman AL, (2005) Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol 175: 2676-2683.
26. Okamoto Y, Kurane I, Leporati AM, Ennis FA, (1998) Definition of the region on NS3 which contains multiple epitopes recognized by dengue virus serotype-cross-reactive and flavivirus-cross-reactive, HLA-DPw2-restricted CD4+ T cell clones. J Gen Virol 79 (Pt 4) (): 697-704.
27. Sanchez V, Gimenez S, Tomlinson B, Chan PK, Thomas GN, et al. (2006) Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine 24: 4914-4926.
28. Zeng L, Kurane I, Okamoto Y, Ennis FA, Brinton MA, (1996) Identification of amino acids involved in recognition by dengue virus NS3-specific, HLA-DR15-restricted cytotoxic CD4+ T-cell clones. J Virol 70: 3108-3117.
29. Zivny J, Kurane I, Leporati AM, Ibe M, Takiguchi M, et al. (1995) A single nine-amino acid peptide induces virus-specific, CD8+ human cytotoxic T lymphocyte clones of heterogeneous serotype specificities. J Exp Med 182: 853-863.
30. Vaughan K, Greenbaum J, Blythe M, Peters B, Sette A, (2010) Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology. Viral Immunol 23: 259-284.
31. Capeding RZ, Brion JD, Caponpon MM, Gibbons RV, Jarman RG, et al. (2010) The incidence, characteristics, and presentation of dengue virus infections during infancy. Am J Trop Med Hyg 82: 330-336.
32. Kanakaratne N, Wahala WM, Messer WB, Tissera HA, Shahani A, et al. (2009) Severe dengue epidemics in Sri Lanka, 2003-2006. Emerg Infect Dis 15: 192-199.
33. Lee KS, Lai YL, Lo S, Barkham T, Aw P, et al. (2010) Dengue virus surveillance for early warning, Singapore. Emerg Infect Dis 16: 847-849.
34. Morrison AC, Minnick SL, Rocha C, Forshey BM, Stoddard ST, et al. (2010) Epidemiology of dengue virus in Iquitos, Peru 1999 to 2005: interepidemic and epidemic patterns of transmission. PLoS Negl Trop Dis 4: e670.
35. Paramasivan R, Dhananjeyan KJ, Leo SV, Muniaraj M, Thenmozhi V, et al. (2010) Dengue fever caused by dengue virus serotype-3 (subtype-III) in a rural area of Madurai district, Tamil Nadu. Indian J Med Res 132: 339-342.
36. Sun J, Lin J, Yan J, Fan W, Lu L, et al. (2011) Dengue virus serotype 3 subtype III, Zhejiang Province, China. Emerg Infect Dis 17: 321-323.
37. Cordeiro MT, Silva AM, Brito CA, Nascimento EJ, Magalhaes MC, et al. (2007) Characterization of a dengue patient cohort in Recife, Brazil. Am J Trop Med Hyg 77: 1128-1134.
38. Cordeiro MT, Schatzmayr HG, Nogueira RM, Oliveira VF, Melo WT, et al. (2007) Dengue and dengue hemorrhagic fever in the State of Pernambuco, 1995-2006. Rev Soc Bras Med Trop 40: 605-611.
39. Maciel M Jr, Kellathur SN, Chikhlikar P, Dhalia R, Sidney J, et al. (2008) Comprehensive analysis of T cell epitope discovery strategies using 17DD yellow fever virus structural proteins and BALB/c (H2d) mice model. Virology 378: 105-117.
40. Lund O, Nascimento EJ, Maciel M Jr, Nielsen M, Larsen MV, et al. (2011) Human leukocyte antigen (HLA) class I restricted epitope discovery in yellow fewer and dengue viruses: importance of HLA binding strength. PLoS One 6: e26494.
41. Pascolo S, (2005) HLA class I transgenic mice: development, utilisation and improvement. Expert Opin Biol Ther 5: 919-938.
42. Simon GG, Hu Y, Khan AM, Zhou J, Salmon J, et al. (2010) Dendritic cell mediated delivery of plasmid DNA encoding LAMP/HIV-1 Gag fusion immunogen enhances T cell epitope responses in HLA DR4 transgenic mice. PLoS One 5: e8574.
43. Toma A, Laika T, Haddouk S, Luce S, Briand JP, et al. (2009) Recognition of human proinsulin leader sequence by class I-restricted T-cells in HLA-A*0201 transgenic mice and in human type 1 diabetes. Diabetes 58: 394-402.
44. Scharnagl NC, Klade CS, (2007) Experimental discovery of T-cell epitopes: combining the best of classical and contemporary approaches. Expert Rev Vaccines 6: 605-615.
45. Khan AM, Miotto O, Nascimento EJ, Srinivasan KN, Heiny AT, et al. (2008) Conservation and variability of dengue virus proteins: implications for vaccine design. PLoS Negl Trop Dis 2: e272.
46. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, et al. (1997) HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185: 2043-2051.
47. Rohrlich PS, Cardinaud S, Firat H, Lamari M, Briand P, et al. (2003) HLA-B*0702 transgenic, H-2KbDb double-knockout mice: phenotypical and functional characterization in response to influenza virus. Int Immunol 15: 765-772.
48. Vandenbark AA, Rich C, Mooney J, Zamora A, Wang C, et al. (2003) Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice. J Immunol 171: 127-133.
49. Madsen L, Labrecque N, Engberg J, Dierich A, Svejgaard A, et al. (1999) Mice lacking all conventional MHC class II genes. Proc Natl Acad Sci U S A 96: 10338-10343.
50. Strauss G, Vignali DA, Schonrich G, Hammerling GJ, (1994) Negative and positive selection by HLA-DR3(DRw17) molecules in transgenic mice. Immunogenetics 40: 104-108.
51. Ito K, Bian HJ, Molina M, Han J, Magram J, et al. (1996) HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med 183: 2635-2644.
52. Roederer M, Koup RA, (2003) Optimized determination of T cell epitope responses. J Immunol Methods 274: 221-228.
53. Tan PT, Heiny AT, Miotto O, Salmon J, Marques ET, et al. (2010) Conservation and diversity of influenza A H1N1 HLA-restricted T cell epitope candidates for epitope-based vaccines. PLoS One 5: e8754.
54. Alencar L, Braga-Neto UM, Nascimento EJM, Cordeiro MT, Silva AM, et al. (2013) HLA-B*44 Is Associated with Dengue Severity Caused by DENV-3 in a Brazilian Population. Journal of Tropical Medicine 2013doi:10.1155/2013/648475.
55. de Melo AB, da Silva Mda P, Magalhaes MC, Gonzales Gil LH, Freese de Carvalho EM, et al. (2011) Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg 85: 739-747.
56. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, et al. (2004) alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 64: 5934-5937.
57. Nielsen M, Lund O, (2009) NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics 10: 296.
58. Nielsen M, Lundegaard C, Lund O, (2007) Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics 8: 238.
59. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, et al. (1999) Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 17: 555-561.
60. Greenbaum J, Sidney J, Chung J, Brander C, Peters B, et al. (2011) Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics 63: 325-335.
61. Sidney J, Assarsson E, Moore C, Ngo S, Pinilla C, et al. (2008) Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res 4: 2.
62. Sidney J, Southwood S, Oseroff C, del Guercio MF, Sette A, et al. (2001) Measurement of MHC/peptide interactions by gel filtration. Curr Protoc Immunol Chapter 18: Unit 18 13.
63. Sidney J, Steen A, Moore C, Ngo S, Chung J, et al. (2010) Divergent motifs but overlapping binding repertoires of six HLA-DQ molecules frequently expressed in the worldwide human population. J Immunol 185: 4189-4198.
64. Sidney J, Steen A, Moore C, Ngo S, Chung J, et al. (2010) Five HLA-DP molecules frequently expressed in the worldwide human population share a common HLA supertypic binding specificity. J Immunol 184: 2492-2503.
65. Buchli R, VanGundy RS, Hickman-Miller HD, Giberson CF, Bardet W, et al. (2004) Real-time measurement of in vitro peptide binding to soluble HLA-A*0201 by fluorescence polarization. Biochemistry 43: 14852-14863.
66. Sette A, Rappuoli R, (2010) Reverse vaccinology: developing vaccines in the era of genomics. Immunity 33: 530-541.
67. Jung KO, Khan AM, Tan BY, Hu Y, Simon GG, et al. (2012) West nile virus T-cell ligand sequences shared with other flaviviruses: a multitude of variant sequences as potential altered Peptide ligands. J Virol 86: 7616-7624.
68. Fruci D, Lauvau G, Saveanu L, Amicosante M, Butler RH, et al. (2003) Quantifying recruitment of cytosolic peptides for HLA class I presentation: impact of TAP transport. J Immunol 170: 2977-2984.
69. de Melo AB, Nascimento EJ, Braga-Neto U, Dhalia R, Silva AM, et al. (2013) T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and-II binding motifs. PLoS Negl Trop Dis 7: e1938.
70. Mailliard RB, Smith KN, Fecek RJ, Rappocciolo G, Nascimento EJ, et al. (2013) Selective Induction of CTL Helper Rather Than Killer Activity by Natural Epitope Variants Promotes Dendritic Cell-Mediated HIV-1 Dissemination. J Immunol 191: 2570-80 doi: 10.4049/jimmunol.1300373.
71. Hertz T, Nolan D, James I, John M, Gaudieri S, et al. (2011) Mapping the landscape of host-pathogen coevolution: HLA class I binding and its relationship with evolutionary conservation in human and viral proteins. J Virol 85: 1310-1321.
72. Thomas SJ, Eckels KH, Carletti I, De La Barrera R, Dessy F, et al. (2013) A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg 88: 73-88.
73. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, et al. (2012) Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380: 1559-1567.
74. Guy B, Nougarede N, Begue S, Sanchez V, Souag N, et al. (2008) Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 26: 5712-5721.
75. Gwinn W, Sun W, Innis BL, Caudill J, King AD, (2003) Serotype-specific T(H)1 responses in recipients of two doses of candidate live-attenuated dengue virus vaccines. Am J Trop Med Hyg 69: 39-47.
76. Harenberg A, Begue S, Mamessier A, Gimenez-Fourage S, Ching Seah C, et al. (2013) Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore. Hum Vaccin Immunother 9doi:10.4161/hv.25562.